APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Heterozygous Familial Hypercholesterolemia Drug

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Heterozygous Familial Hypercholesterolemia Drug Industry Growth and Trends Forecast to 2032

Report ID 173998390119 December 202570 pages

Choose your research edition.

Industry ResearchHeterozygous Familial Hypercholesterolemia Drug Industry Research Report 2026106 pages · $2,950 USDIndustry Growth & TrendsGlobal Heterozygous Familial Hypercholesterolemia Drug Industry Growth and Trends Forecast to 203270 pages · $3,450 USDMarket StructureGlobal Heterozygous Familial Hypercholesterolemia Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032174 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Heterozygous Familial Hypercholesterolemia Drug Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Heterozygous Familial Hypercholesterolemia Drug Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Heterozygous Familial Hypercholesterolemia Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Heterozygous Familial Hypercholesterolemia Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Heterozygous Familial Hypercholesterolemia Drug is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Heterozygous Familial Hypercholesterolemia Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Heterozygous Familial Hypercholesterolemia Drug include Madrigal Pharmaceuticals Inc, Gemphire Therapeutics Inc, Esperion Therapeutics Inc and Daewoong Co Ltd, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Heterozygous Familial Hypercholesterolemia Drug market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Heterozygous Familial Hypercholesterolemia Drug market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Heterozygous Familial Hypercholesterolemia Drug market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Heterozygous Familial Hypercholesterolemia Drug.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Heterozygous Familial Hypercholesterolemia Drug market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Heterozygous Familial Hypercholesterolemia Drug Market by Company

Madrigal Pharmaceuticals Inc

Gemphire Therapeutics Inc

Esperion Therapeutics Inc

Daewoong Co Ltd

Heterozygous Familial Hypercholesterolemia Drug Segment by Type

Gemcabene Calcium

ST-103

MGL-3196

Others

Heterozygous Familial Hypercholesterolemia Drug Segment by Application

Clinic

Hospital

Others

Heterozygous Familial Hypercholesterolemia Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Heterozygous Familial Hypercholesterolemia Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Heterozygous Familial Hypercholesterolemia Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Heterozygous Familial Hypercholesterolemia Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Heterozygous Familial Hypercholesterolemia Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Heterozygous Familial Hypercholesterolemia Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Gemcabene Calcium Table 2. Major Company of ST-103 Table 3. Major Company of MGL-3196 Table 4. Major Company of Others Table 5. Global Heterozygous Familial Hypercholesterolemia Drug Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 6. Global Heterozygous Familial Hypercholesterolemia Drug Sales by Type (2021-2026) & (K Units) Table 7. Global Heterozygous Familial Hypercholesterolemia Drug Sales Market Share in Volume by Type (2021-2026) Table 8. Global Heterozygous Familial Hypercholesterolemia Drug Sales by Type (2021-2026) & (US$ Million) Table 9. Global Heterozygous Familial Hypercholesterolemia Drug Sales Market Share in Value by Type (2021-2026) Table 10. Global Heterozygous Familial Hypercholesterolemia Drug Price by Type (2021-2026) & (US$/Unit) Table 11. Global Heterozygous Familial Hypercholesterolemia Drug Sales by Type (2027-2032) & (K Units) Table 12. Global Heterozygous Familial Hypercholesterolemia Drug Sales Market Share in Volume by Type (2027-2032) Table 13. Global Heterozygous Familial Hypercholesterolemia Drug Sales by Type (2027-2032) & (US$ Million) Table 14. Global Heterozygous Familial Hypercholesterolemia Drug Sales Market Share in Value by Type (2027-2032) Table 15. Global Heterozygous Familial Hypercholesterolemia Drug Price by Type (2027-2032) & (US$/Unit) Table 16. North America Heterozygous Familial Hypercholesterolemia Drug Sales by Type (2021-2026) & (K Units) Table 17. North America Heterozygous Familial Hypercholesterolemia Drug Sales by Type (2021-2026) & (US$ Million) Table 18. Europe Heterozygous Familial Hypercholesterolemia Drug Sales by Type (2021-2026) & (K Units) Table 19. Europe Heterozygous Familial Hypercholesterolemia Drug Sales by Type (2021-2026) & (US$ Million) Table 20. Asia-Pacific Heterozygous Familial Hypercholesterolemia Drug Sales by Type (2021-2026) & (K Units) Table 21. Asia-Pacific Heterozygous Familial Hypercholesterolemia Drug Sales by Type (2021-2026) & (US$ Million) Table 22. Latin America Heterozygous Familial Hypercholesterolemia Drug Sales by Type (2021-2026) & (K Units) Table 23. Latin America Heterozygous Familial Hypercholesterolemia Drug Sales by Type (2021-2026) & (US$ Million) Table 24. Middle East and Africa Heterozygous Familial Hypercholesterolemia Drug Sales by Type (2021-2026) & (K Units) Table 25. Middle East and Africa Heterozygous Familial Hypercholesterolemia Drug Sales by Type (2021-2026) & (US$ Million) Table 26. Heterozygous Familial Hypercholesterolemia Drug Industry Trends Table 27. Heterozygous Familial Hypercholesterolemia Drug Industry Drivers Table 28. Heterozygous Familial Hypercholesterolemia Drug Industry Opportunities and Challenges Table 29. Heterozygous Familial Hypercholesterolemia Drug Industry Restraints Table 30. Global Heterozygous Familial Hypercholesterolemia Drug Sales Revenue by Company (US$ Million) & (2021-2026) Table 31. Global Heterozygous Familial Hypercholesterolemia Drug Revenue Market Share by Company (2021-2026) Table 32. Global Heterozygous Familial Hypercholesterolemia Drug Sales by Company (2021-2026) & (K Units) Table 33. Global Heterozygous Familial Hypercholesterolemia Drug Sales Share by Company (2021-2026) Table 34. Global Heterozygous Familial Hypercholesterolemia Drug Market Price by Company (2021-2026) & (US$/Unit) Table 35. Global Heterozygous Familial Hypercholesterolemia Drug Industry Company Ranking, 2024 VS 2025 VS 2026 Table 36. Global Heterozygous Familial Hypercholesterolemia Drug Major Company Production Sites and Headquarters Table 37. Global Heterozygous Familial Hypercholesterolemia Drug Company, Product Type & Application Table 38. Global Heterozygous Familial Hypercholesterolemia Drug Company Establishment Date Table 39. Global Company Market Concentration Ratio (CR5 and HHI) Table 40. Global Heterozygous Familial Hypercholesterolemia Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 41. Global Heterozygous Familial Hypercholesterolemia Drug Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 42. Global Heterozygous Familial Hypercholesterolemia Drug Sales by Region (2021-2026) & (K Units) Table 43. Global Heterozygous Familial Hypercholesterolemia Drug Sales Market Share in Volume by Region (2021-2026) Table 44. Global Heterozygous Familial Hypercholesterolemia Drug Sales by Region (2021-2026) & (US$ Million) Table 45. Global Heterozygous Familial Hypercholesterolemia Drug Sales Market Share in Value by Region (2021-2026) Table 46. Global Heterozygous Familial Hypercholesterolemia Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 47. Global Heterozygous Familial Hypercholesterolemia Drug Sales by Region (2027-2032) & (K Units) Table 48. Global Heterozygous Familial Hypercholesterolemia Drug Sales Market Share in Volume by Region (2027-2032) Table 49. Global Heterozygous Familial Hypercholesterolemia Drug Sales by Region (2027-2032) & (US$ Million) Table 50. Global Heterozygous Familial Hypercholesterolemia Drug Sales Market Share in Value by Region (2027-2032) Table 51. Global Heterozygous Familial Hypercholesterolemia Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 52. Global Heterozygous Familial Hypercholesterolemia Drug Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 53. Global Heterozygous Familial Hypercholesterolemia Drug Sales by Application (2021-2026) & (K Units) Table 54. Global Heterozygous Familial Hypercholesterolemia Drug Sales Market Share in Volume by Application (2021-2026) Table 55. Global Heterozygous Familial Hypercholesterolemia Drug Sales by Application (2021-2026) & (US$ Million) Table 56. Global Heterozygous Familial Hypercholesterolemia Drug Sales Market Share in Value by Application (2021-2026) Table 57. Global Heterozygous Familial Hypercholesterolemia Drug Price by Application (2021-2026) & (US$/Unit) Table 58. Global Heterozygous Familial Hypercholesterolemia Drug Sales by Application (2027-2032) & (K Units) Table 59. Global Heterozygous Familial Hypercholesterolemia Drug Sales Market Share in Volume by Application (2027-2032) Table 60. Global Heterozygous Familial Hypercholesterolemia Drug Sales by Application (2027-2032) & (US$ Million) Table 61. Global Heterozygous Familial Hypercholesterolemia Drug Sales Market Share in Value by Application (2027-2032) Table 62. Global Heterozygous Familial Hypercholesterolemia Drug Price by Application (2027-2032) & (US$/Unit) Table 63. North America Heterozygous Familial Hypercholesterolemia Drug Sales by Application (2021-2026) & (K Units) Table 64. North America Heterozygous Familial Hypercholesterolemia Drug Sales by Application (2021-2026) & (US$ Million) Table 65. Europe Heterozygous Familial Hypercholesterolemia Drug Sales by Application (2021-2026) & (K Units) Table 66. Europe Heterozygous Familial Hypercholesterolemia Drug Sales by Application (2021-2026) & (US$ Million) Table 67. Asia-Pacific Heterozygous Familial Hypercholesterolemia Drug Sales by Application (2021-2026) & (K Units) Table 68. Asia-Pacific Heterozygous Familial Hypercholesterolemia Drug Sales by Application (2021-2026) & (US$ Million) Table 69. Latin America Heterozygous Familial Hypercholesterolemia Drug Sales by Application (2021-2026) & (K Units) Table 70. Latin America Heterozygous Familial Hypercholesterolemia Drug Sales by Application (2021-2026) & (US$ Million) Table 71. Middle East and Africa Heterozygous Familial Hypercholesterolemia Drug Sales by Application (2021-2026) & (K Units) Table 72. Middle East and Africa Heterozygous Familial Hypercholesterolemia Drug Sales by Application (2021-2026) & (US$ Million) Table 73. Madrigal Pharmaceuticals Inc Company Information Table 74. Madrigal Pharmaceuticals Inc Business Overview Table 75. Madrigal Pharmaceuticals Inc Heterozygous Familial Hypercholesterolemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Madrigal Pharmaceuticals Inc Heterozygous Familial Hypercholesterolemia Drug Product Portfolio Table 77. Madrigal Pharmaceuticals Inc Recent Development Table 78. Gemphire Therapeutics Inc Company Information Table 79. Gemphire Therapeutics Inc Business Overview Table 80. Gemphire Therapeutics Inc Heterozygous Familial Hypercholesterolemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Gemphire Therapeutics Inc Heterozygous Familial Hypercholesterolemia Drug Product Portfolio Table 82. Gemphire Therapeutics Inc Recent Development Table 83. Esperion Therapeutics Inc Company Information Table 84. Esperion Therapeutics Inc Business Overview Table 85. Esperion Therapeutics Inc Heterozygous Familial Hypercholesterolemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Esperion Therapeutics Inc Heterozygous Familial Hypercholesterolemia Drug Product Portfolio Table 87. Esperion Therapeutics Inc Recent Development Table 88. Daewoong Co Ltd Company Information Table 89. Daewoong Co Ltd Business Overview Table 90. Daewoong Co Ltd Heterozygous Familial Hypercholesterolemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Daewoong Co Ltd Heterozygous Familial Hypercholesterolemia Drug Product Portfolio Table 92. Daewoong Co Ltd Recent Development Table 93. North America Heterozygous Familial Hypercholesterolemia Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 94. North America Heterozygous Familial Hypercholesterolemia Drug Sales by Country (2021-2026) & (K Units) Table 95. North America Heterozygous Familial Hypercholesterolemia Drug Sales Market Share by Country (2021-2026) Table 96. North America Heterozygous Familial Hypercholesterolemia Drug Sales Forecast by Country (2027-2032) & (K Units) Table 97. North America Heterozygous Familial Hypercholesterolemia Drug Sales Market Share Forecast by Country (2027-2032) Table 98. North America Heterozygous Familial Hypercholesterolemia Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 99. North America Heterozygous Familial Hypercholesterolemia Drug Market Size by Country (2021-2026) & (US$ Million) Table 100. North America Heterozygous Familial Hypercholesterolemia Drug Market Share by Country (2021-2026) Table 101. North America Heterozygous Familial Hypercholesterolemia Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 102. North America Heterozygous Familial Hypercholesterolemia Drug Market Share Forecast by Country (2027-2032) Table 103. Europe Heterozygous Familial Hypercholesterolemia Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 104. Europe Heterozygous Familial Hypercholesterolemia Drug Sales by Country (2021-2026) & (K Units) Table 105. Europe Heterozygous Familial Hypercholesterolemia Drug Sales Market Share by Country (2021-2026) Table 106. Europe Heterozygous Familial Hypercholesterolemia Drug Sales Forecast by Country (2027-2032) & (K Units) Table 107. Europe Heterozygous Familial Hypercholesterolemia Drug Sales Market Share Forecast by Country (2027-2032) Table 108. Europe Heterozygous Familial Hypercholesterolemia Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 109. Europe Heterozygous Familial Hypercholesterolemia Drug Market Size by Country (2021-2026) & (US$ Million) Table 110. Europe Heterozygous Familial Hypercholesterolemia Drug Market Share by Country (2021-2026) Table 111. Europe Heterozygous Familial Hypercholesterolemia Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 112. Europe Heterozygous Familial Hypercholesterolemia Drug Market Share Forecast by Country (2027-2032) Table 113. Asia-Pacific Heterozygous Familial Hypercholesterolemia Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 114. Asia-Pacific Heterozygous Familial Hypercholesterolemia Drug Sales by Country (2021-2026) & (K Units) Table 115. Asia-Pacific Heterozygous Familial Hypercholesterolemia Drug Sales Market Share by Country (2021-2026) Table 116. Asia-Pacific Heterozygous Familial Hypercholesterolemia Drug Sales Forecast by Country (2027-2032) & (K Units) Table 117. Asia-Pacific Heterozygous Familial Hypercholesterolemia Drug Sales Market Share Forecast by Country (2027-2032) Table 118. Asia-Pacific Heterozygous Familial Hypercholesterolemia Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 119. Asia-Pacific Heterozygous Familial Hypercholesterolemia Drug Market Size by Country (2021-2026) & (US$ Million) Table 120. Asia-Pacific Heterozygous Familial Hypercholesterolemia Drug Market Share by Country (2021-2026) Table 121. Asia-Pacific Heterozygous Familial Hypercholesterolemia Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 122. Asia-Pacific Heterozygous Familial Hypercholesterolemia Drug Market Share Forecast by Country (2027-2032) Table 123. Latin America Heterozygous Familial Hypercholesterolemia Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 124. Latin America Heterozygous Familial Hypercholesterolemia Drug Sales by Country (2021-2026) & (K Units) Table 125. Latin America Heterozygous Familial Hypercholesterolemia Drug Sales Market Share by Country (2021-2026) Table 126. Latin America Heterozygous Familial Hypercholesterolemia Drug Sales Forecast by Country (2027-2032) & (K Units) Table 127. Latin America Heterozygous Familial Hypercholesterolemia Drug Sales Market Share Forecast by Country (2027-2032) Table 128. Latin America Heterozygous Familial Hypercholesterolemia Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 129. Latin America Heterozygous Familial Hypercholesterolemia Drug Market Size by Country (2021-2026) & (US$ Million) Table 130. Latin America Heterozygous Familial Hypercholesterolemia Drug Market Share by Country (2021-2026) Table 131. Latin America Heterozygous Familial Hypercholesterolemia Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 132. Latin America Heterozygous Familial Hypercholesterolemia Drug Market Share Forecast by Country (2027-2032) Table 133. Middle East and Africa Heterozygous Familial Hypercholesterolemia Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 134. Middle East and Africa Heterozygous Familial Hypercholesterolemia Drug Sales by Country (2021-2026) & (K Units) Table 135. Middle East and Africa Heterozygous Familial Hypercholesterolemia Drug Sales Market Share by Country (2021-2026) Table 136. Middle East and Africa Heterozygous Familial Hypercholesterolemia Drug Sales Forecast by Country (2027-2032) & (K Units) Table 137. Middle East and Africa Heterozygous Familial Hypercholesterolemia Drug Sales Market Share Forecast by Country (2027-2032) Table 138. Middle East and Africa Heterozygous Familial Hypercholesterolemia Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 139. Middle East and Africa Heterozygous Familial Hypercholesterolemia Drug Market Size by Country (2021-2026) & (US$ Million) Table 140. Middle East and Africa Heterozygous Familial Hypercholesterolemia Drug Market Share by Country (2021-2026) Table 141. Middle East and Africa Heterozygous Familial Hypercholesterolemia Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 142. Middle East and Africa Heterozygous Familial Hypercholesterolemia Drug Market Share Forecast by Country (2027-2032) Table 143. Key Raw Materials Table 144. Raw Materials Key Suppliers Table 145. Heterozygous Familial Hypercholesterolemia Drug Distributors List Table 146. Heterozygous Familial Hypercholesterolemia Drug Customers List Table 147. Research Programs/Design for This Report Table 148. Authors List of This Report Table 149. Secondary Sources Table 150. Primary Sources List of Figures Figure 1. Heterozygous Familial Hypercholesterolemia Drug Image Figure 2. Global Heterozygous Familial Hypercholesterolemia Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Heterozygous Familial Hypercholesterolemia Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Heterozygous Familial Hypercholesterolemia Drug Sales (2021-2032) & (K Units) Figure 5. Gemcabene Calcium Image Figure 6. Global Gemcabene Calcium Sales YoY Growth (2021-2032) & (K Units) Figure 7. ST-103 Image Figure 8. Global ST-103 Sales YoY Growth (2021-2032) & (K Units) Figure 9. MGL-3196 Image Figure 10. Global MGL-3196 Sales YoY Growth (2021-2032) & (K Units) Figure 11. Others Image Figure 12. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 13. Global Heterozygous Familial Hypercholesterolemia Drug Market Size Overview by Type (2021-2032) & (US$ Million) Figure 14. Global Heterozygous Familial Hypercholesterolemia Drug Market Share by Type 2025 VS 2032 Figure 15. North America Heterozygous Familial Hypercholesterolemia Drug Sales Market Share in Volume by Type in 2025 Figure 16. North America Heterozygous Familial Hypercholesterolemia Drug Sales Market Share in Value by Type in 2025 Figure 17. Europe Heterozygous Familial Hypercholesterolemia Drug Sales Market Share in Volume by Type in 2025 Figure 18. Europe Heterozygous Familial Hypercholesterolemia Drug Sales Market Share in Value by Type in 2025 Figure 19. Asia-Pacific Heterozygous Familial Hypercholesterolemia Drug Sales Market Share in Volume by Type in 2025 Figure 20. Asia-Pacific Heterozygous Familial Hypercholesterolemia Drug Sales Market Share in Value by Type in 2025 Figure 21. Latin America Heterozygous Familial Hypercholesterolemia Drug Sales Market Share in Volume by Type in 2025 Figure 22. Latin America Heterozygous Familial Hypercholesterolemia Drug Sales Market Share in Value by Type in 2025 Figure 23. Middle East and Africa Heterozygous Familial Hypercholesterolemia Drug Sales Market Share in Volume by Type in 2025 Figure 24. Middle East and Africa Heterozygous Familial Hypercholesterolemia Drug Sales Market Share in Value by Type in 2025 Figure 25. Global Top 5 and 10 Heterozygous Familial Hypercholesterolemia Drug Players Market Share by Revenue in 2025 Figure 26. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Clinic Image Figure 28. Global Clinic Sales YoY Growth (2021-2032) & (K Units) Figure 29. Hospital Image Figure 30. Global Hospital Sales YoY Growth (2021-2032) & (K Units) Figure 31. Others Image Figure 32. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 33. Global Heterozygous Familial Hypercholesterolemia Drug Market Size Overview by Application (2021-2032) & (US$ Million) Figure 34. Global Heterozygous Familial Hypercholesterolemia Drug Market Share by Application 2025 VS 2032 Figure 35. North America Heterozygous Familial Hypercholesterolemia Drug Sales Market Share in Volume by Application in 2025 Figure 36. North America Heterozygous Familial Hypercholesterolemia Drug Sales Market Share in Value by Application in 2025 Figure 37. Europe Heterozygous Familial Hypercholesterolemia Drug Sales Market Share in Volume by Application in 2025 Figure 38. Europe Heterozygous Familial Hypercholesterolemia Drug Sales Market Share in Value by Application in 2025 Figure 39. Asia-Pacific Heterozygous Familial Hypercholesterolemia Drug Sales Market Share in Volume by Application in 2025 Figure 40. Asia-Pacific Heterozygous Familial Hypercholesterolemia Drug Sales Market Share in Value by Application in 2025 Figure 41. Latin America Heterozygous Familial Hypercholesterolemia Drug Sales Market Share in Volume by Application in 2025 Figure 42. Latin America Heterozygous Familial Hypercholesterolemia Drug Sales Market Share in Value by Application in 2025 Figure 43. Middle East and Africa Heterozygous Familial Hypercholesterolemia Drug Sales Market Share in Volume by Application in 2025 Figure 44. Middle East and Africa Heterozygous Familial Hypercholesterolemia Drug Sales Market Share in Value by Application in 2025 Figure 45. North America Heterozygous Familial Hypercholesterolemia Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 46. North America Heterozygous Familial Hypercholesterolemia Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. North America Heterozygous Familial Hypercholesterolemia Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. North America Heterozygous Familial Hypercholesterolemia Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Heterozygous Familial Hypercholesterolemia Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 50. Europe Heterozygous Familial Hypercholesterolemia Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Heterozygous Familial Hypercholesterolemia Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Europe Heterozygous Familial Hypercholesterolemia Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Heterozygous Familial Hypercholesterolemia Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 54. Asia-Pacific Heterozygous Familial Hypercholesterolemia Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Heterozygous Familial Hypercholesterolemia Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Asia-Pacific Heterozygous Familial Hypercholesterolemia Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Heterozygous Familial Hypercholesterolemia Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 58. Latin America Heterozygous Familial Hypercholesterolemia Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Heterozygous Familial Hypercholesterolemia Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Latin America Heterozygous Familial Hypercholesterolemia Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Heterozygous Familial Hypercholesterolemia Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 62. Middle East and Africa Heterozygous Familial Hypercholesterolemia Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Heterozygous Familial Hypercholesterolemia Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Middle East and Africa Heterozygous Familial Hypercholesterolemia Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Heterozygous Familial Hypercholesterolemia Drug Value Chain Figure 66. Key Raw Materials Price Figure 67. Manufacturing Cost Structure Figure 68. Heterozygous Familial Hypercholesterolemia Drug Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Gemcabene Calcium
  • ST-103
  • MGL-3196
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • Madrigal Pharmaceuticals Inc
  • Gemphire Therapeutics Inc
  • Esperion Therapeutics Inc
  • Daewoong Co Ltd

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Heterozygous Familial Hypercholesterolemia Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Heterozygous Familial Hypercholesterolemia Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Heterozygous Familial Hypercholesterolemia Drug Market by Type
  6. 1.3.1 Gemcabene Calcium
  7. 1.3.2 ST-103
  8. 1.3.3 MGL-3196
  9. 1.3.4 Others
  10. 1.4 Global Heterozygous Familial Hypercholesterolemia Drug Market Size by Type
  11. 1.4.1 Global Heterozygous Familial Hypercholesterolemia Drug Market Size Overview by Type (2021-2032)
  12. 1.4.2 Global Heterozygous Familial Hypercholesterolemia Drug Historic Market Size Review by Type (2021-2026)
  13. 1.4.3 Global Heterozygous Familial Hypercholesterolemia Drug Forecasted Market Size by Type (2027-2032)
  14. 1.5 Key Regions Market Size by Type
  15. 1.5.1 North America Heterozygous Familial Hypercholesterolemia Drug Sales Breakdown by Type (2021-2026)
  16. 1.5.2 Europe Heterozygous Familial Hypercholesterolemia Drug Sales Breakdown by Type (2021-2026)
  17. 1.5.3 Asia-Pacific Heterozygous Familial Hypercholesterolemia Drug Sales Breakdown by Type (2021-2026)
  18. 1.5.4 South America Heterozygous Familial Hypercholesterolemia Drug Sales Breakdown by Type (2021-2026)
  19. 1.5.5 Middle East and Africa Heterozygous Familial Hypercholesterolemia Drug Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Heterozygous Familial Hypercholesterolemia Drug Industry Trends
  2. 2.2 Heterozygous Familial Hypercholesterolemia Drug Industry Drivers
  3. 2.3 Heterozygous Familial Hypercholesterolemia Drug Industry Opportunities and Challenges
  4. 2.4 Heterozygous Familial Hypercholesterolemia Drug Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Heterozygous Familial Hypercholesterolemia Drug Revenue (2021-2026)
  2. 3.2 Global Top Players by Heterozygous Familial Hypercholesterolemia Drug Sales (2021-2026)
  3. 3.3 Global Top Players by Heterozygous Familial Hypercholesterolemia Drug Price (2021-2026)
  4. 3.4 Global Heterozygous Familial Hypercholesterolemia Drug Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Heterozygous Familial Hypercholesterolemia Drug Major Company Production Sites & Headquarters
  6. 3.6 Global Heterozygous Familial Hypercholesterolemia Drug Company, Product Type & Application
  7. 3.7 Global Heterozygous Familial Hypercholesterolemia Drug Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Heterozygous Familial Hypercholesterolemia Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Heterozygous Familial Hypercholesterolemia Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Heterozygous Familial Hypercholesterolemia Drug Tier 1, Tier 2, and Tier 3
4 Heterozygous Familial Hypercholesterolemia Drug Regional Status and Outlook
  1. 4.1 Global Heterozygous Familial Hypercholesterolemia Drug Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Heterozygous Familial Hypercholesterolemia Drug Historic Market Size by Region
  3. 4.2.1 Global Heterozygous Familial Hypercholesterolemia Drug Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Heterozygous Familial Hypercholesterolemia Drug Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Heterozygous Familial Hypercholesterolemia Drug Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Heterozygous Familial Hypercholesterolemia Drug Forecasted Market Size by Region
  7. 4.3.1 Global Heterozygous Familial Hypercholesterolemia Drug Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Heterozygous Familial Hypercholesterolemia Drug Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Heterozygous Familial Hypercholesterolemia Drug Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Heterozygous Familial Hypercholesterolemia Drug by Application
  1. 5.1 Heterozygous Familial Hypercholesterolemia Drug Market by Application
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Others
  5. 5.2 Global Heterozygous Familial Hypercholesterolemia Drug Market Size by Application
  6. 5.2.1 Global Heterozygous Familial Hypercholesterolemia Drug Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Heterozygous Familial Hypercholesterolemia Drug Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Heterozygous Familial Hypercholesterolemia Drug Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Heterozygous Familial Hypercholesterolemia Drug Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Heterozygous Familial Hypercholesterolemia Drug Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Heterozygous Familial Hypercholesterolemia Drug Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Heterozygous Familial Hypercholesterolemia Drug Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Heterozygous Familial Hypercholesterolemia Drug Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Madrigal Pharmaceuticals Inc
  2. 6.1.1 Madrigal Pharmaceuticals Inc Company Information
  3. 6.1.2 Madrigal Pharmaceuticals Inc Business Overview
  4. 6.1.3 Madrigal Pharmaceuticals Inc Heterozygous Familial Hypercholesterolemia Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Madrigal Pharmaceuticals Inc Heterozygous Familial Hypercholesterolemia Drug Product Portfolio
  6. 6.1.5 Madrigal Pharmaceuticals Inc Recent Developments
  7. 6.2 Gemphire Therapeutics Inc
  8. 6.2.1 Gemphire Therapeutics Inc Company Information
  9. 6.2.2 Gemphire Therapeutics Inc Business Overview
  10. 6.2.3 Gemphire Therapeutics Inc Heterozygous Familial Hypercholesterolemia Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Gemphire Therapeutics Inc Heterozygous Familial Hypercholesterolemia Drug Product Portfolio
  12. 6.2.5 Gemphire Therapeutics Inc Recent Developments
  13. 6.3 Esperion Therapeutics Inc
  14. 6.3.1 Esperion Therapeutics Inc Company Information
  15. 6.3.2 Esperion Therapeutics Inc Business Overview
  16. 6.3.3 Esperion Therapeutics Inc Heterozygous Familial Hypercholesterolemia Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Esperion Therapeutics Inc Heterozygous Familial Hypercholesterolemia Drug Product Portfolio
  18. 6.3.5 Esperion Therapeutics Inc Recent Developments
  19. 6.4 Daewoong Co Ltd
  20. 6.4.1 Daewoong Co Ltd Company Information
  21. 6.4.2 Daewoong Co Ltd Business Overview
  22. 6.4.3 Daewoong Co Ltd Heterozygous Familial Hypercholesterolemia Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Daewoong Co Ltd Heterozygous Familial Hypercholesterolemia Drug Product Portfolio
  24. 6.4.5 Daewoong Co Ltd Recent Developments
7 North America by Country
  1. 7.1 North America Heterozygous Familial Hypercholesterolemia Drug Sales by Country
  2. 7.1.1 North America Heterozygous Familial Hypercholesterolemia Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Heterozygous Familial Hypercholesterolemia Drug Sales by Country (2021-2026)
  4. 7.1.3 North America Heterozygous Familial Hypercholesterolemia Drug Sales Forecast by Country (2027-2032)
  5. 7.2 North America Heterozygous Familial Hypercholesterolemia Drug Market Size by Country
  6. 7.2.1 North America Heterozygous Familial Hypercholesterolemia Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Heterozygous Familial Hypercholesterolemia Drug Market Size by Country (2021-2026)
  8. 7.2.3 North America Heterozygous Familial Hypercholesterolemia Drug Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Heterozygous Familial Hypercholesterolemia Drug Sales by Country
  2. 8.1.1 Europe Heterozygous Familial Hypercholesterolemia Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Heterozygous Familial Hypercholesterolemia Drug Sales by Country (2021-2026)
  4. 8.1.3 Europe Heterozygous Familial Hypercholesterolemia Drug Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Heterozygous Familial Hypercholesterolemia Drug Market Size by Country
  6. 8.2.1 Europe Heterozygous Familial Hypercholesterolemia Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Heterozygous Familial Hypercholesterolemia Drug Market Size by Country (2021-2026)
  8. 8.2.3 Europe Heterozygous Familial Hypercholesterolemia Drug Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Heterozygous Familial Hypercholesterolemia Drug Sales by Country
  2. 9.1.1 Asia-Pacific Heterozygous Familial Hypercholesterolemia Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Heterozygous Familial Hypercholesterolemia Drug Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Heterozygous Familial Hypercholesterolemia Drug Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Heterozygous Familial Hypercholesterolemia Drug Market Size by Country
  6. 9.2.1 Asia-Pacific Heterozygous Familial Hypercholesterolemia Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Heterozygous Familial Hypercholesterolemia Drug Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Heterozygous Familial Hypercholesterolemia Drug Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Heterozygous Familial Hypercholesterolemia Drug Sales by Country
  2. 10.1.1 South America Heterozygous Familial Hypercholesterolemia Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Heterozygous Familial Hypercholesterolemia Drug Sales by Country (2021-2026)
  4. 10.1.3 South America Heterozygous Familial Hypercholesterolemia Drug Sales Forecast by Country (2027-2032)
  5. 10.2 South America Heterozygous Familial Hypercholesterolemia Drug Market Size by Country
  6. 10.2.1 South America Heterozygous Familial Hypercholesterolemia Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Heterozygous Familial Hypercholesterolemia Drug Market Size by Country (2021-2026)
  8. 10.2.3 South America Heterozygous Familial Hypercholesterolemia Drug Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Heterozygous Familial Hypercholesterolemia Drug Sales by Country
  2. 11.1.1 Middle East and Africa Heterozygous Familial Hypercholesterolemia Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Heterozygous Familial Hypercholesterolemia Drug Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Heterozygous Familial Hypercholesterolemia Drug Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Heterozygous Familial Hypercholesterolemia Drug Market Size by Country
  6. 11.2.1 Middle East and Africa Heterozygous Familial Hypercholesterolemia Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Heterozygous Familial Hypercholesterolemia Drug Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Heterozygous Familial Hypercholesterolemia Drug Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Heterozygous Familial Hypercholesterolemia Drug Value Chain Analysis
  2. 12.1.1 Heterozygous Familial Hypercholesterolemia Drug Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Heterozygous Familial Hypercholesterolemia Drug Production Mode & Process
  7. 12.2 Heterozygous Familial Hypercholesterolemia Drug Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Heterozygous Familial Hypercholesterolemia Drug Distributors
  10. 12.2.3 Heterozygous Familial Hypercholesterolemia Drug Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst